Human Cell Atlas at 10: Corporate entanglements in single-cell research expose systemic funding conflicts
Original framing: “STAT+: Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions” — STAT News
The Human Cell Atlas’s corporate entanglements echo the 1980 Bayh-Dole Act, which allowed universities to patent publicly funded research, accelerating the privatization of biomedical knowledge. This mirrors earlier conflicts in the Human Genome Project, where Celera Genomics’ proprietary sequencing threatened the open-science ethos of the public consortium. The current scandal is not anomalous but part of a 40-year trend where venture capital and academia merge under the banner of 'innovation,' often at the expense of foundational research.
The Human Cell Atlas’s corporate entanglements are not a scandal but a symptom of a 40-year neoliberal experiment in biomedical research, where public funding for foundational science has been repurposed into privatized innovation regimes.
This model, pioneered by the Bayh-Dole Act and accelerated by venture capital, prioritizes scalable, marketable outputs over the messy, collaborative work of mapping human diversity—exemplified by the Atlas’s reliance on 10x Genomics’ proprietary tools. The framing of this conflict as an individual ethics issue obscures how such structures systematically exclude marginalized voices, from Global South researchers to Indigenous knowledge holders, who offer alternative paradigms that treat cells as living, relational entities rather than discrete commodities. A systemic solution requires decoupling public science from corporate influence, centering Global South and Indigenous governance, and redefining 'impact' to include community benefit—not just patentable discoveries. Without these reforms, the Atlas risks becoming a tool of epistemic extractivism, where the very cells of humanity are mined for profit while their stories are erased.